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Overall Survival in SHH-MB patients

Medulloblastoma (MB) is the most common tumor of the
central nervous system in children with high metastasis
rate and ineffective therapies.
We previously found the upregulated expression of the
RE1-Silencing Transcription Factor (REST), a repressor
of neurogenesis, to be associated with poor survival in
patients with Sonic Hedgehog (SHH) subgroup of MBs.
Through a loss of function screen, we identified DNA
methyltransferase 1 (DNMT1) as a high-priority candidate
that is critical for the viability of tumor cells in the context
of REST elevation in SHH-MBs.
Hypothesis: We assume that REST is altering DNA
methylation and gene expression in SHH-MB.

Figure 3: Overall survival of Sonic Hedgehog
Medulloblastoma patients with High- and Low-REST
levels over 20 years. High-REST patients (n=22)
have worse overall survival probability compared to
that of low-REST patients (n=40) (p<0.05).
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Figure 1: A loss of function
screen identifies DNMT1 as a
high priority candidate that is
critical for the viability of
tumor cells in the context of
REST elevation in SHH-MBs.
The knockdown of DNMT1
blocks cell growth of highREST cells.
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Figure 4: Volcano plots showing the DNA methylation differences based on REST levels in SHH-Medulloblastoma at all sites in
three different genomic locations. Each red dot on the positive scale represents a hypermethylated CpG site in high-REST SHHMBs. Blue dot on the negative scale represents a hypomethylated CpG site in high-REST SHH-MBs. CpG sites in CGIs (CpG
islands) are more hypermethylated when REST levels are high than in shore, shelf and non-CGI (4.3% vs 3.9% and 1.7%)
respectively; p<0.05; DNA methylation difference > |10%|. A. DNA methylation differences between high-REST SHH-MBs and
low-REST SHH-MBs at CpG island in CGIs. B. CpG sites at shore and shelf. C. CpG sites at non-CGIs.
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• REST elevation in SHH-MBs is
associated with poor survival. REST
elevation
promotes
tumor
cell
proliferation and the knockdown of
DNMT1 blocks REST-dependent cell
growth.
• Compared to tumors with low REST
expression, samples with higher REST
expression exhibit hypermethylation at
the promoter, gene body and intergenic
locations.
• There is a negative correlation between
gene expression and DNA methylation in
high-REST genes at the transcription
start site in the promoter region that is
still ongoing.
• Hypermethylated genes play a role in
development
and
differentiation
processes of cancer.

Future Work
Figure 5: Volcano plots showing the DNA methylation differences between high-REST SHH-MBs and low-REST SHH-MBs at the
promoter region in three different genomic locations. CpG sites at the promoter in CpG island (CGIs) showed a lower
hypomethylation percentage than that in shore, shelf, and n-CGI (0.06% vs 0.8% and 1.9%) respectively; p<0.05; DNA methylation
difference > |10%|. A. DNA methylation differences and REST levels at the promoter in CGIs. B. Promoter at shore and shelf. C.
Promoter at non-CGIs.

Gene expression differences in
context of REST levels

Correlation between gene
expression and DNA methylation

20226 genes

1- Overall

Figure 2: Flow chart showing the research strategy. Patient data was divided into two groups
based on the average of REST mRNA levels.

Figure 5: Bar graph of the percentage of DNA methylation of all sites at
three genomic locations (CGI, shore and shelf, and non-CGI) of highREST SHH-MB patients. A. CpG sites at CGIs showed higher ratio of
hypermethylated sites than at shore and shelf and non-CGIs. B. CpG
sites at non-CGIs are prone to hypomethylation compared to CGIs and
shore and shelf.
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Figure 6: Volcano plot
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Survival in SHH-MB
2- DNA methylation differences in REST context
3- Gene expression differences in REST context
4- Validation in human MB cell lines (DAOY, UW228, and UW426)
5- Validation in overlapped genes in mice model (RESTTG and WT)
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To detect the effects of REST upregulation on DNA
methylation status and the overall survival, we analyzed a
publicly available database and divided the SHH-MBs into
two groups based on REST levels expression (high-REST
and low-REST). Overall survival graphs are generated for
both groups as well as volcano plots showing the DNA
methylation differences and REST levels at different genomic
locations. We also detected the correlation between gene
expression and DNA methylation changes. Genes with
significant DNA methylation changes were chosen for
pathway analysis. Chosen genes are validated in human MB
cell lines as well as in mice model.
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Molecular and cellular functions
p-value range # Molecules
Cell-To-Cell Signaling and Interaction 3.39E-02 - 5.90E-07
13
Molecular Transport
3.15E-02 - 5.90E-07
21
Small Molecule Biochemistry
3.15E-02 - 5.90E-07
16
Cell Morphology
2.91E-02 - 8.85E-05
8
Cellular Assembly and Organization 3.39E-02 - 8.85E-05
11
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p-value range # Molecules
3.39E-02 - 1.25E-07
57
3.39E-02 - 1.25E-07
58
3.39E-02 - 1.91E-06
51
2.71E-02 - 9.35E-06
13
3.39E-02 - 9.35E-06
43

Table 2: Pathway analysis showing the molecular and cellular
functions as well as the p-value range and number of molecules
that the 58 chosen genes with downregulated expression and DNA
hypermethylation are involved in.

Sites (%)

low-REST

0

Diseases and disorders name
Cancer
Organismal Injury and Abnormalities
Endocrine System Disorders
Cardiovascular Disease
Neurological Disease

Table 1: Pathway analysis showing the name of the diseases and
disorders as well as the p-value range and number of molecules
that the 58 chosen genes with downregulated expression and DNA
hypermethylation are involved in.

DNMT1
r=0.89
p<0.0001

Pathway Analysis
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Figure 7: Correlation graph
representing
a
nonsignificant
correlation
between gene expression
differences
and
DNA
methylation differences in
high- and low- REST CpG
sites at the promoter in
9827 genes. 41 genes in
red
represent
hypermethylation with gene
expression upregulation; 58
genes in blue represent
hypermethylation with gene
expression downregulation.

• RNA sequencing to identify the
disrupted events of the initiation,
splicing, and elongation of transcription
in high-REST SHH-MB.
• Validation in human MB cell lines
(DOAY, UW228, and UW426) through
bisulfite
pyrosequencing
and
quantitative RT-PCR.
• Validation in SHH-MB mice model
(RESTTG and WT).
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